Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Synaptic Density in Amnestic Mild Cognitive Impairment
NCT06041152Phase 2Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in amnestic mild cognitive impairment (MCI), sponsored by Center for Addiction and Mental Health. Started Nov 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT06041152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041152.